## 3 Results
### Pre-Hospitalisation Treatment  
Before admission, eight patients (16.33%) with erythroderric psoriasis underwent steroid treatment. Among them, five (10.20%) were treated with topical steroids, and one received a combination of both topical and systemic steroids. For the remaining cases, information on whether it was topical or systemic therapy was unavailable. Methotrexate was administered to six patients (12.24%), acitretin to eight (16.33%), and two (4.08%) patients who received cyclosporine. Phototherapy was administered in eleven cases (22.45%), dithranol in three (6.12%), and biological treatments in two (4.08%). A subset of therapies was combined. Data on pre-hospitalization treatment in twenty-one patients (42.86%) was incomplete, and specific treatment details were not collected for this group. Additionally, eleven patients (22.45%) with erythroderric psoriasis received treatment for comorbiditiesbefore hospitalization, predominantly with antihypertensive drugs. This included five patients (10.20%) receiving angiotensin-converting enzyme inhibitors, two receiving calcium channel blockers (4.08%), five receiving beta-blockers (10.20%), and five receiving diuretics (10.20%). Moreover, five patients were treated with anticoagulants (10.20%) and one with antidiabetic medication (2.04%). However, due to the lack of data in many cases and the small sample sizes in these groups, further statistical analyses were not performed, as it could be considered insignificant. In erythroderma due to atopic dermatitis, nine (33.33%) patients received steroid treatment, including two (7.41%) with topical steroids. For other cases, information on whether it was systemic or topical steroids was lacking. Four (14.81%) patients underwent phototherapy, six (22.22%) were treated with immunosuppressive (including two with cyclosporine and one with acitretin), and in three (11.11%) patients, the specific immunosuppressive drug administered could not be established. Additionally, nine (33.33%) patients received antihistamines. The treatments were combined. Data was incomplete or unspecific in twelve (44.44%) cases. Among the eleven (40.74%) patients with erythroderma caused by atopic dermatitis, treatment for comorbidities was administered, with antihypertensive drugs predominating, followed by beta-2 mimetics. Specifically, three (11.11%) patients were treated with angiotensin-converting enzyme inhibitors, four (14.81%) with beta-blockers, and two (7.41%) with diuretics. Beta-2 mimetics were administered to four (14.81%) patients. Additionally, two (7.41%) patients received anticoagulants, two (7.41%) were prescribed antidiabetic drugs, and two (7.41%) were given antidepressants. Patients with CTCL were treated with steroids in nineteen cases (70.37%), with four (14.81%) of them receiving systemic steroids and one receiving (3.70%) both topical and systemic treatment. Data concerning the type of steroid used for fifteen (55.55%) patients was incomplete. Immunosupressants were administered to thirteen (48.14%) patients, including four (14.81%) treated with methotrexate and one (3.70%) with cyclosporine. For the remaining cases, data on the specific immunosuppressive drug used were incomplete. Other cases included three receiving retinoids (11.11%) and fifteen (55.55%) undergoing phototherapy. Some therapies were combined. Additionally, nine (33.33%) were treated with antihistamines. In the case of CTCL, six (22.22%) patients underwent therapy for comorbidities, primarily for hypertension, with one (3.70%) patient receiving angiotensin-converting enzyme inhibitors and two (7.41%) receiving beta-blockers. Furthermore, one (3.70%) patient received anticoagulants, another was prescribed antidiabetic drugs, and one underwent antidepressant therapy. In five (18.52%) cases, data were incomplete, and authors could not establish pre-hospitalization treatment.